Moxonidine tab n / 0.2mg film about 14 pieces of ozone


Moxonidine tab n / 0.2mg film about 14 pieces of ozone



Active substance:
1 tablet contains: moxonidine – 0.200 mg and 0.400 mg.
Product form:
Tablets, film-coated 0.2 mg and 0.4 mg. At 7, 10, 14 tablets were placed in blisters of PVC film and aluminum foil printed patent. 10, 20, 30, 40, 50, 60 or 100 tablets were placed in cans or jars made of polyethylene terephthalate polymer for medicaments. One jar or 1,2,3,4,5,6,7,8,9 or 10 contour of cellular packaging together with instructions for use placed in a cardboard box (pack).
– Increased sensitivity to the drug; – bradycardia (.. The heart rate (HR) of less than 50 beats / min) or severe bradyarrhythmia, including sinus syndrome, atrioventricular block II and III degree; – hemodynamically significant cardiac arrhythmias; – severe chronic heart failure III-IV NYHA functional class classification; – the use in patients aged 75 years and older; – severe renal impairment (creatinine clearance less than 30 mL / min, serum creatinine 160 umol / L); – lactase deficiency, lactose intolerance, glucose-galactose malabsorption; – the age of 18 years (effectiveness and safety have been established); – concomitant use of tricyclic antidepressants; – due to lack of experience in the application, you should avoid taking moxonidine in patients with concomitant “intermittent” claudication, Raynaud’s disease, Parkinson’s disease, epilepsy, glaucoma and depression.
0.2 mg
Arterial hypertension.
pharmachologic effect
Pharmacological group:
Centrally acting antihypertensive agent.
Pharmacological properties:
Moxonidine – selective imidazoline receptor agonists. Selectively interacting with I1-imidazoline receptors located in the brain stem, reduces sympathetic activity. Moxonidine has high affinity for imidazoline I1-receptor binds only marginally and with the central alpha2-adrenoceptors, by the interaction which is explained dryness of the oral mucosa and sedation. Decreases Resistance to insulin stimulates the release of growth hormone. Effect on hemodynamics: reduction in systolic and diastolic blood pressure (BP) and after a single long-term treatment is associated with a decrease of moxonidine pressor actions of the sympathetic system in peripheral vessels, reduced peripheral vascular resistance, while the cardiac output and heart rate did not significantly change. The maximum antihypertensive effect is reached after about 2.5-7 hours after ingestion.
Conditions of supply of pharmacies
Dosing and Administration
Tablets are inside, regardless of food intake, drinking plenty of fluids. In most instances the drug Moxonidine is administered in an initial dose of 0.2 mg per once, preferably in the morning. When insufficient therapeutic effect of the dose can be increased after 3 weeks of treatment, up to 0.4 mg a day for two steps or a single dose; if after 3 weeks of treatment, response to treatment will be unsatisfactory, it is possible to increase the dose to 0.6 mg, divided in 2 divided doses (morning and evening). The starting dose for patients with renal failure (creatinine clearance of 30-60 ml / min) is 0.2 mg. Where appropriate and well tolerated daily dose may be increased to 0.4 mg. In elderly patients with normal renal function, the recommendations are the same as for adult patients. Start treatment with the lowest dose and the subsequent increase in dose made with caution. Use of the drug in patients 75 years and older is contraindicated.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg

OZONE generics

There are no reviews yet.

Add your review